RODABE NAMARIARODABE N AMARIA9898AMARIA, RODABE NAssistant Professorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson1400 Holcombe BlvdHouston77030-4008TXAuthorship 1813631Authorship 188750118952560Amaria RN, Corboy JR, Finlayson CA, Robinson WA, Borges VFClinical breast cancerImmunomodulatory therapy in multiple sclerosis and breast cancer risk: a case report and literature review. Clin Breast Cancer. 2008 Oct; 8(5):449-52.Clin Breast Cancer2008-10-01T00:00:002008Immunomodulatory therapy in multiple sclerosis and breast cancer risk: a case report and literature review.21957431Amaria RN, Lewis KD, Gonzalez RTherapeutic advances in medical oncologyTherapeutic options in cutaneous melanoma: latest developments. Ther Adv Med Oncol. 2011 Sep; 3(5):245-51.Ther Adv Med Oncol2011-09-01T00:00:002011Therapeutic options in cutaneous melanoma: latest developments.Melanoma Medical OncologySurgical OncologyMD AndersonJEFFREY EGERSHENWALDJEFFREY E GERSHENWALD8667GERSHENWALD, JEFFREY EProfessorJENNIFERWARGOJENNIFER WARGO9904WARGO, JENNIFERAssociate ProfessorMICHAELTETZLAFFMICHAEL TETZLAFF9684TETZLAFF, MICHAELAssociate ProfessorADIDIABADI DIAB9901DIAB, ADIAssistant ProfessorMICHAEL ADAVIESMICHAEL A DAVIES8753DAVIES, MICHAEL AAssociate ProfessorVICTORPRIETOVICTOR PRIETO8828PRIETO, VICTORProfessorPATRICKHWUPATRICK HWU9108HWU, PATRICKProfessor4.7810.00829146286research areas4.623640.032131136coauthor of123.59124.256460similar to1198selected publicationsAuthorship 2343462Authorship 235195123807941Medina T, Amaria MN, Jimeno ADrugs of today (Barcelona, Spain : 1998)Dabrafenib in the treatment of advanced melanoma. Drugs Today (Barc). 2013 Jun; 49(6):377-85.Drugs Today (Barc)2013-06-01T00:00:002013Dabrafenib in the treatment of advanced melanoma.24720932Amaria RN, Kim KBExpert opinion on pharmacotherapyDabrafenib for the treatment of melanoma. Expert Opin Pharmacother. 2014 May; 15(7):1043-50.Expert Opin Pharmacother2014-04-10T00:00:002014Dabrafenib for the treatment of melanoma.Authorship 258549222091682Scheier B, Amaria R, Lewis K, Gonzalez RImmunotherapyNovel therapies in melanoma. Immunotherapy. 2011 Dec; 3(12):1461-9.Immunotherapy2011-12-01T00:00:002011Novel therapies in melanoma.Authorship 271796224072401Jordan KR, Amaria RN, Ramirez O, Callihan EB, Gao D, Borakove M, Manthey E, Borges VF, McCarter MDCancer immunology, immunotherapy : CIIMyeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. Cancer Immunol Immunother. 2013 Nov; 62(11):1711-22.Cancer Immunol Immunother2013-09-27T00:00:002013Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients.Authorship 273202315622958Hutton J, Wasmeier C, Amaria R, Bright N, Creemers JAdvances in experimental medicine and biologyProprotein processing and pancreatic islet function. Adv Exp Med Biol. 2004; 552:39-65.Adv Exp Med Biol2004-01-01T00:00:002004Proprotein processing and pancreatic islet function.Authorship 29090818Authorship 2935516Authorship 2941212Authorship 2946655Authorship 299241425148578Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MAThe Journal of investigative dermatologyBeyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015 Feb; 135(2):508-515.J Invest Dermatol2014-08-22T00:00:002014Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.25564571Gerami P, Cook RW, Wilkinson J, Russell MC, Dhillon N, Amaria RN, Gonzalez R, Lyle S, Johnson CE, Oelschlager KM, Jackson GL, Greisinger AJ, Maetzold D, Delman KA, Lawson DH, Stone JFClinical cancer research : an official journal of the American Association for Cancer ResearchDevelopment of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res. 2015 Jan 01; 21(1):175-83.Clin Cancer Res2015-01-01T00:00:002015Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma.25610709Kim T, Amaria RN, Spencer C, Reuben A, Cooper ZA, Wargo JACancer biology & medicineCombining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma. Cancer Biol Med. 2014 Dec; 11(4):237-46.Cancer Biol Med2014-12-01T00:00:002014Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma.25748297Gerami P, Cook RW, Russell MC, Wilkinson J, Amaria RN, Gonzalez R, Lyle S, Jackson GL, Greisinger AJ, Johnson CE, Oelschlager KM, Stone JF, Maetzold DJ, Ferris LK, Wayne JD, Cooper C, Obregon R, Delman KA, Lawson DJournal of the American Academy of DermatologyGene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. J Am Acad Dermatol. 2015 May; 72(5):780-5.e3.J Am Acad Dermatol2015-03-03T00:00:002015Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy.26440571Schmitt RJ, Kreidler SM, Glueck DH, Amaria RN, Gonzalez R, Lewis K, Bagrosky BM, Kwak JJ, Koo PJNuclear medicine communicationsCorrelation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma. Nucl Med Commun. 2016 Feb; 37(2):122-8.Nucl Med Commun2016-02-01T00:00:002016Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma.74Professor10Assistant Professor14Associate ProfessorHUSSEINTAWBIHUSSEIN TAWBI11940TAWBI, HUSSEINAssociate Professor26645196Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL, Bosenberg MW, Woodman SE, Overwijk WW, Liz?e G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA, Hwu PCancer discoveryLoss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 6(2):202-16.Cancer Discov2015-12-08T00:00:002015Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.27911979Kim DW, Haydu LE, Joon AY, Bassett RL, Siroy AE, Tetzlaff MT, Routbort MJ, Amaria RN, Wargo JA, McQuade JL, Kemnade J, Hwu P, Woodman SE, Roszik J, Kim KB, Gershenwald JE, Lazar AJ, Davies MACancerClinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients. Cancer. 2017 04 15; 123(8):1372-1381.Cancer2016-12-02T00:00:002016Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients.Authorship 842593Authorship 850127Authorship 853295Authorship 853788Authorship 855741Authorship 858540Authorship 862236Authorship 863477Authorship 865813Expert Review of DermatologyAdjuvant peginterferon alfa-2b therapy in stage III melanoma. Expert Review of Dermatology. 6:567-575.Adjuvant peginterferon alfa-2b therapy in stage III melanomaCancer DiscoveryCancer Discovery. 6:202-216.Cancer DiscoveryNuclear Medicine CommunicationsCorrelation between early <sup>18</sup>F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma. Nuclear Medicine Communications. 37:122-128.Correlation between early <sup>18</sup>F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanomaOncoImmunologyDistinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. OncoImmunology. 5.Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanomaCancerClinicopathological features and clinical outcomes associated with TP53 and BRAF<sup>N</sup> <sup>on-</sup> <sup>V</sup> <sup>600</sup> mutations in cutaneous melanoma patients. Cancer. Clinicopathological features and clinical outcomes associated with TP53 and BRAF<sup>N</sup> <sup>on-</sup> <sup>V</sup> <sup>600</sup> mutations in cutaneous melanoma patientsCancer Biology and MedicineCombining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma. Cancer Biology and Medicine. 11:237-246.Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanomaMelanoma ResearchA phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma. Melanoma Research. A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanomaGastrointestinal Cancer ResearchSelective internal radiotherapy in metastatic esophageal adenocarcinoma. Gastrointestinal Cancer Research. 4:191-193.Selective internal radiotherapy in metastatic esophageal adenocarcinomaCancer DiscoveryAnalysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discovery. 6:827-837.Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade29267866McKenzie JA, Mbofung RM, Malu S, Zhang M, Ashkin E, Devi S, Williams L, Tieu T, Peng W, Pradeep S, Xu C, Zorro Manrique S, Liu C, Huang L, Chen Y, Forget MA, Haymaker C, Bernatchez C, Satani N, Muller F, Roszik J, Kalra A, Heffernan T, Sood A, Hu J, Amaria R, Davis RE, Hwu PJournal of the National Cancer InstituteThe Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy. J Natl Cancer Inst. 2018 07 01; 110(7):777-786.J Natl Cancer Inst2018-07-01T00:00:002018The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy.29496759Huang L, Malu S, McKenzie JA, Andrews MC, Talukder AH, Tieu T, Karpinets T, Haymaker C, Forget MA, Williams LJ, Wang Z, Mbofung RM, Wang ZQ, Davis RE, Lo RS, Wargo JA, Davies MA, Bernatchez C, Heffernan T, Amaria RN, Korkut A, Peng W, Roszik J, Liz?e G, Woodman SE, Hwu PClinical cancer research : an official journal of the American Association for Cancer ResearchThe RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. Clin Cancer Res. 2018 07 15; 24(14):3366-3376.Clin Cancer Res2018-03-01T00:00:002018The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression.28878208Mbofung RM, McKenzie JA, Malu S, Zhang M, Peng W, Liu C, Kuiatse I, Tieu T, Williams L, Devi S, Ashkin E, Xu C, Huang L, Zhang M, Talukder AH, Tripathi SC, Khong H, Satani N, Muller FL, Roszik J, Heffernan T, Allison JP, Lizee G, Hanash SM, Proia D, Amaria R, Davis RE, Hwu PNature communicationsHSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. Nat Commun. 2017 09 06; 8(1):451.Nat Commun2017-09-06T00:00:002017HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes.29628419Cascone T, McKenzie JA, Mbofung RM, Punt S, Wang Z, Xu C, Williams LJ, Wang Z, Bristow CA, Carugo A, Peoples MD, Li L, Karpinets T, Huang L, Malu S, Creasy C, Leahey SE, Chen J, Chen Y, Pelicano H, Bernatchez C, Gopal YNV, Heffernan TP, Hu J, Wang J, Amaria RN, Garraway LA, Huang P, Yang P, Wistuba II, Woodman SE, Roszik J, Davis RE, Davies MA, Heymach JV, Hwu P, Peng WCell metabolismIncreased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metab. 2018 May 01; 27(5):977-987.e4.Cell Metab2018-04-05T00:00:002018Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy.Authorship 8881568Authorship 88833819Authorship 88867925Authorship 88904326Authorship 88991826Authorship 89003626D007167Procedures83233380.374551ImmunotherapyD020360Procedures66449650.385167Neoadjuvant TherapyD010091Chemicals & Drugs881760.885153OximesD012878Disorders71446250.304279Skin NeoplasmsAuthorship 90707712Authorship 9072331Authorship 90769311Authorship 9100923Authorship 91172121Authorship 91279031Authorship 9145682Authorship 9146622Authorship 9151045Authorship 91535918Authorship 91559910Authorship 91851536Authorship 9189654Authorship 91899913Authorship 91948114Authorship 91966722Authorship 9202969Authorship 92217832Authorship 92377914Authorship 92407618Authorship 9250504Authorship 92509144Authorship 9300711Authorship 9306991Authorship 9309662Authorship 9353022Authorship 9373641Authorship 9388492Authorship 9399531Authorship 9399841425941608Cooper ZA, Reuben A, Amaria RN, Wargo JAOncoimmunologyEvidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma. Oncoimmunology. 2014 Oct; 3(9):e954956.Oncoimmunology2014-12-13T00:00:002014Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma.27301722Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JACancer discoveryAnalysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37.Cancer Discov2016-06-14T00:00:002016Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.27141370Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JAOncoimmunologyDistinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology. 2016 Mar; 5(3):e1136044.Oncoimmunology2016-02-02T00:00:002016Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma.27124486Chen G, McQuade JL, Panka DJ, Hudgens CW, Amin-Mansour A, Mu XJ, Bahl S, Jan?-Valbuena J, Wani KM, Reuben A, Creasy CA, Jiang H, Cooper ZA, Roszik J, Bassett RL, Joon AY, Simpson LM, Mouton RD, Glitza IC, Patel SP, Hwu WJ, Amaria RN, Diab A, Hwu P, Lazar AJ, Wargo JA, Garraway LA, Tetzlaff MT, Sullivan RJ, Kim KB, Davies MAJAMA oncologyClinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol. 2016 Aug 01; 2(8):1056-64.JAMA Oncol2016-08-01T00:00:002016Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.27471714Amaria RN, Reuben A, Cooper ZA, Wargo JAImmunoTargets and therapyUpdate on use of aldesleukin for treatment of high-risk metastatic melanoma. Immunotargets Ther. 2015; 4:79-89.Immunotargets Ther2015-04-07T00:00:002015Update on use of aldesleukin for treatment of high-risk metastatic melanoma.27540836McQuade JL, Posada LP, Lecagoonporn S, Cain S, Bassett RL, Patel SP, Hwu WJ, Hwu P, Davies MA, Bedikian AY, Amaria RNMelanoma researchA phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma. Melanoma Res. 2016 12; 26(6):604-608.Melanoma Res2016-12-01T00:00:002016A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma.28251903Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PAScience translational medicineIntegrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017 03 01; 9(379).Sci Transl Med2017-03-01T00:00:002017Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.28680759Qin Y, Petaccia de Macedo M, Reuben A, Forget MA, Haymaker C, Bernatchez C, Spencer CN, Gopalakrishnan V, Reddy S, Cooper ZA, Fulbright OJ, Ramachandran R, Wahl A, Flores E, Thorsen ST, Tavera RJ, Conrad C, Williams MD, Tetzlaff MT, Wang WL, Gombos DS, Esmaeli B, Amaria RN, Hwu P, Wargo JA, Lazar AJ, Patel SPOncoimmunologyParallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. Oncoimmunology. 2017; 6(6):e1321187.Oncoimmunology2017-05-08T00:00:002017Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study.28824634Forget MA, Tavera RJ, Haymaker C, Ramachandran R, Malu S, Zhang M, Wardell S, Fulbright OJ, Toth CL, Gonzalez AM, Thorsen ST, Flores E, Wahl A, Peng W, Amaria RN, Hwu P, Bernatchez CFrontiers in immunologyA Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes. Front Immunol. 2017; 8:908.Front Immunol2017-08-02T00:00:002017A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes.28901560Tetzlaff MT, Jazaeri AA, Torres-Cabala CA, Korivi BR, Landon GA, Nagarajan P, Choksi A, Chen L, Uemura M, Aung PP, Diab A, Sharma P, Davies MA, Amaria R, Prieto VG, Curry JLJournal of cutaneous pathologyErythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients. J Cutan Pathol. 2017 Dec; 44(12):1080-1086.J Cutan Pathol2017-10-13T00:00:002017Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients.29165790Brusco LL, Wathoo C, Mills Shaw KR, Holla VR, Bailey AM, Johnson AM, Khotskaya YB, Litzenburger BC, Sanchez NS, Zeng J, Bernstam EV, Eng C, Kee BK, Amaria RN, Routbort MJ, Mills GB, Mendelsohn J, Meric-Bernstam FCancerPhysician interpretation of genomic test results and treatment selection. Cancer. 2018 03 01; 124(5):966-972.Cancer2017-11-22T00:00:002017Physician interpretation of genomic test results and treatment selection.28817446Glitza IC, Guha-Thakurta N, D'Souza NM, Amaria RN, McGovern SL, Rao G, Li JMelanoma researchBevacizumab as an effective treatment for radiation necrosis after radiotherapy for melanoma brain metastases. Melanoma Res. 2017 12; 27(6):580-584.Melanoma Res2017-12-01T00:00:002017Bevacizumab as an effective treatment for radiation necrosis after radiotherapy for melanoma brain metastases.28819565Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JANPJ genomic medicineGenomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med. 2017; 2.NPJ Genom Med2017-04-07T00:00:002017Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.29250602Reuben A, Amaria RN, Cooper ZA, Wargo JAJournal of pigmentary disordersRAF Inhibitor Therapy Promotes Melanocytic Antigen Expression and Enhanced Anti-Tumor Immunity in Melanoma. J Pigment Disord. 2014 Nov; 1(5).J Pigment Disord2014-10-16T00:00:002014RAF Inhibitor Therapy Promotes Melanocytic Antigen Expression and Enhanced Anti-Tumor Immunity in Melanoma.29387478Glitza IC, Rohlfs M, Guha-Thakurta N, Bassett RL, Bernatchez C, Diab A, Woodman SE, Yee C, Amaria RN, Patel SP, Tawbi H, Wong M, Hwu WJ, Hwu P, Heimberger A, McCutcheon IE, Papadopoulos N, Davies MAESMO openRetrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open. 2018; 3(1):e000283.ESMO Open2018-01-24T00:00:002018Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2.29672900Farah M, Nagarajan P, Torres-Cabala CA, Curry JL, Amaria RN, Wargo J, Tawbi H, Ivan D, Prieto VG, Tetzlaff MT, Aung PPJournal of cutaneous pathologyMetastatic melanoma with balloon/histiocytoid cytomorphology after treatment with immunotherapy: A histologic mimic and diagnostic pitfall. J Cutan Pathol. 2018 Jul; 45(7):545-549.J Cutan Pathol2018-05-18T00:00:002018Metastatic melanoma with balloon/histiocytoid cytomorphology after treatment with immunotherapy: A histologic mimic and diagnostic pitfall.29848573Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez CClinical cancer research : an official journal of the American Association for Cancer ResearchProspective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clin Cancer Res. 2018 09 15; 24(18):4416-4428.Clin Cancer Res2018-05-30T00:00:002018Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.29361468Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JAThe Lancet. OncologyNeoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193.Lancet Oncol2018-01-18T00:00:002018Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.29433571Tetzlaff MT, Nelson KC, Diab A, Staerkel GA, Nagarajan P, Torres-Cabala CA, Chasen BA, Wargo JA, Prieto VG, Amaria RN, Curry JLJournal for immunotherapy of cancerGranulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. J Immunother Cancer. 2018 02 12; 6(1):14.J Immunother Cancer2018-02-12T00:00:002018Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients.29496665Romano G, Chen PL, Song P, McQuade JL, Liang RJ, Liu M, Roh W, Duose DY, Carapeto FCL, Li J, Teh JLF, Aplin AE, Chen M, Zhang J, Lazar AJ, Davies MA, Futreal PA, Amaria RN, Zhang DY, Wargo JA, Kwong LNCancer discoveryA Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Cancer Discov. 2018 05; 8(5):556-567.Cancer Discov2018-03-01T00:00:002018A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling.29665030Dolkar T, Trinidad CM, Nelson KC, Amaria RN, Nagarajan P, Torres-Cabala CA, Ivan D, Prieto VG, Tetzlaff MT, Curry JL, Aung PPJournal of cutaneous pathologyDermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: A detailed examination of the clinicopathologic features. J Cutan Pathol. 2018 Jul; 45(7):539-544.J Cutan Pathol2018-05-16T00:00:002018Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: A detailed examination of the clinicopathologic features.29152725Mauzo SH, Tetzlaff MT, Nelson K, Amaria R, Patel S, Aung PP, Nagarajan P, Torres-Cabala CA, Diab A, Prieto VG, Curry JLInternational journal of dermatologyRegressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade. Int J Dermatol. 2019 Sep; 58(9):1045-1052.Int J Dermatol2017-11-20T00:00:002017Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade.29757889Tavera RJ, Forget MA, Kim YU, Sakellariou-Thompson D, Creasy CA, Bhatta A, Fulbright OJ, Ramachandran R, Thorsen ST, Flores E, Wahl A, Gonzalez AM, Toth C, Wardell S, Mansaray R, Radvanyi LG, Gombos DS, Patel SP, Hwu P, Amaria RN, Bernatchez C, Haymaker CJournal of immunotherapy (Hagerstown, Md. : 1997)Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma. J Immunother. 2018 Nov/Dec; 41(9):399-405.J Immunother2018-11-01T00:00:002018Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma.30195813McKean MA, Amaria RNCancer treatment reviewsMultidisciplinary treatment strategies in high-risk resectable melanoma: Role of adjuvant and neoadjuvant therapy. Cancer Treat Rev. 2018 Nov; 70:144-153.Cancer Treat Rev2018-08-29T00:00:002018Multidisciplinary treatment strategies in high-risk resectable melanoma: Role of adjuvant and neoadjuvant therapy.30039289McKean MA, Amaria RNAmerican journal of clinical dermatologyChallenges and Opportunities of Neoadjuvant Treatment in Locally Advanced Melanoma. Am J Clin Dermatol. 2018 Oct; 19(5):639-646.Am J Clin Dermatol2018-10-01T00:00:002018Challenges and Opportunities of Neoadjuvant Treatment in Locally Advanced Melanoma.30713594Forget MA, Haymaker C, Amaria RN, Bernatchez COncotargetTIL therapy and anti-CTLA4: can they co-exist? Oncotarget. 2019 Jan 01; 10(1):1-2.Oncotarget2019-01-01T00:00:002019TIL therapy and anti-CTLA4: can they co-exist?30297909Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JANature medicineNeoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 11; 24(11):1649-1654.Nat Med2018-10-08T00:00:002018Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.30305177Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies MA, Wong MK, Woodman S, Hwu WJ, Hwu P, Wang Y, Diab AJournal for immunotherapy of cancerInfliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer. 2018 10 11; 6(1):103.J Immunother Cancer2018-10-11T00:00:002018Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis.30361510Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JANature medicineAuthor Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1941.Nat Med2018-12-01T00:00:002018Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.30361511Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JANature medicinePublisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1942.Nat Med2018-12-01T00:00:002018Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.D008545Disorders68053010.290119MelanomaPathologyAuthorship 9411111Authorship 941787230815041Pelster MS, Amaria RNTherapeutic advances in medical oncologyCombined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials. Ther Adv Med Oncol. 2019; 11:1758835919830826.Ther Adv Med Oncol2019-02-19T00:00:002019Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials.30776211Amaria R, Caffrey MThe American journal of managed careFinding the right combination for neoadjuvant therapy in high-risk, stage III melanoma. Am J Manag Care. 2019 02; 25(2 Spec No.):SP43-SP44.Am J Manag Care2019-02-01T00:00:002019Finding the right combination for neoadjuvant therapy in high-risk, stage III melanoma.Authorship 9452201430995944Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies MA, Wong MK, Woodman S, Hwu WJ, Hwu P, Wang Y, Diab AJournal for immunotherapy of cancerCorrection to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer. 2019 Apr 17; 7(1):107.J Immunother Cancer2019-04-17T00:00:002019Correction to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis.Authorship 951066131267972Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA, International Neoadjuvant Melanoma Consortium members, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GVThe Lancet. OncologyNeoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol. 2019 07; 20(7):e378-e389.Lancet Oncol2019-07-01T00:00:002019Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.Authorship 953573531398264Schvartsman G, Ma J, Bassett RL, Haydu LE, Amaria RN, Hwu P, Wong MK, Hwu WJ, Diab A, Patel SP, Davies MA, Hamerschlak N, Tawbi HA, Glitza Oliva ICCancerIncidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma. Cancer. 2019 Dec 01; 125(23):4193-4202.Cancer2019-08-09T00:00:002019Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma.Authorship 958004631658370Holbrook K, Lutzky J, Davies MA, Davis JM, Glitza IC, Amaria RN, Diab A, Patel SP, Amin A, Tawbi HCancerIntracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series. Cancer. 2020 02 01; 126(3):523-530.Cancer2019-10-28T00:00:002019Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series.Authorship 9758721431942075Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, Gopalakrishnan V, Xi Y, Zhao H, Amaria RN, Tawbi HA, Cogdill AP, Liu W, LeBleu VS, Kugeratski FG, Patel S, Davies MA, Hwu P, Lee JE, Gershenwald JE, Lucci A, Arora R, Woodman S, Keung EZ, Gaudreau PO, Reuben A, Spencer CN, Burton EM, Haydu LE, Lazar AJ, Zapassodi R, Hudgens CW, Ledesma DA, Ong S, Bailey M, Warren S, Rao D, Krijgsman O, Rozeman EA, Peeper D, Blank CU, Schumacher TN, Butterfield LH, Zelazowska MA, McBride KM, Kalluri R, Allison J, Petitprez F, Fridman WH, Saut?s-Fridman C, Hacohen N, Rezvani K, Sharma P, Tetzlaff MT, Wang L, Wargo JANatureB cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020 01; 577(7791):549-555.Nature2020-01-15T00:00:002020B cells and tertiary lymphoid structures promote immunotherapy response.Authorship 976616431990608Haydu LE, Lo SN, McQuade JL, Amaria RN, Wargo J, Ross MI, Cormier JN, Lucci A, Lee JE, Ferguson SD, Saw RPM, Spillane AJ, Shannon KF, Stretch JR, Hwu P, Patel SP, Diab A, Wong MKK, Glitza Oliva IC, Tawbi H, Carlino MS, Menzies AM, Long GV, Lazar AJ, Tetzlaff MT, Scolyer RA, Gershenwald JE, Thompson JF, Davies MAJournal of clinical oncology : official journal of the American Society of Clinical OncologyCumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. J Clin Oncol. 2020 05 01; 38(13):1429-1441.J Clin Oncol2020-01-28T00:00:002020Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma.Authorship 97735612Authorship 977473232015020Lucci A, Hall CS, Patel SP, Narendran B, Bauldry JB, Royal RE, Karhade M, Upshaw JR, Wargo JA, Glitza IC, Wong MKK, Amaria RN, Tawbi HA, Diab A, Davies MA, Gershenwald JE, Lee JE, Hwu P, Ross MIClinical cancer research : an official journal of the American Association for Cancer ResearchCirculating Tumor Cells and Early Relapse in Node-positive Melanoma. Clin Cancer Res. 2020 04 15; 26(8):1886-1895.Clin Cancer Res2020-02-03T00:00:002020Circulating Tumor Cells and Early Relapse in Node-positive Melanoma.32025932Pelster MS, Amaria RNCurrent treatment options in oncologyNeoadjuvant Immunotherapy for Locally Advanced Melanoma. Curr Treat Options Oncol. 2020 02 05; 21(2):10.Curr Treat Options Oncol2020-02-05T00:00:002020Neoadjuvant Immunotherapy for Locally Advanced Melanoma.Authorship 10037279Authorship 10037932233119140Janku F, Sakamuri D, Kato S, Huang HJ, Call SG, Naing A, Holley VR, Patel SP, Amaria RN, Falchook GS, Piha-Paul SA, Zinner RG, Tsimberidou AM, Hong DS, Meric-Bernstam FCancerDose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers. Cancer. 2021 02 01; 127(3):391-402.Cancer2020-10-29T00:00:002020Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers.33123754Punt S, Malu S, McKenzie JA, Manrique SZ, Doorduijn EM, Mbofung RM, Williams L, Silverman DA, Ashkin EL, Dominguez AL, Wang Z, Chen JQ, Maiti SN, Tieu TN, Liu C, Xu C, Forget MA, Haymaker C, Khalili JS, Satani N, Muller F, Cooper LJN, Overwijk WW, Amaria RN, Bernatchez C, Heffernan TP, Peng W, Roszik J, Hwu PCancer immunology, immunotherapy : CIIAurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity. Cancer Immunol Immunother. 2021 Apr; 70(4):1101-1113.Cancer Immunol Immunother2020-10-29T00:00:002020Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity.Authorship 1006625433294560Duke TC, Nair R, Torres-Cabala C, Amaria RN, Keiser E, Miranda R, Iyer SP, Heberton MJAAD case reportsAngioimmunoblastic T-cell lymphoma associated with immune checkpoint inhibitor treatment. JAAD Case Rep. 2020 Dec; 6(12):1264-1267.JAAD Case Rep2020-10-08T00:00:002020Angioimmunoblastic T-cell lymphoma associated with immune checkpoint inhibitor treatment.Authorship 1010975233558722Menzies AM, Amaria RN, Rozeman EA, Huang AC, Tetzlaff MT, van de Wiel BA, Lo S, Tarhini AA, Burton EM, Pennington TE, Saw RPM, Xu X, Karakousis GC, Ascierto PA, Spillane AJ, van Akkooi ACJ, Davies MA, Mitchell TC, Tawbi HA, Scolyer RA, Wargo JA, Blank CU, Long GVNature medicinePathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med. 2021 02; 27(2):301-309.Nat Med2021-02-08T00:00:002021Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).Authorship 10135001133686688Ogata D, Haydu LE, Glitza IC, Patel SP, Tawbi HA, McQuade JL, Diab A, Ekmekcioglu S, Wong MK, Davies MA, Amaria RNCancer medicineThe efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma. Cancer Med. 2021 04; 10(7):2293-2299.Cancer Med2021-03-08T00:00:002021The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma.Authorship 10163765Authorship 1016422433856603Mitra D, Ologun G, Keung EZ, Goepfert RP, Amaria RN, Ross MI, Gershenwald JE, Lucci A, Fisher SB, Davies MA, Lee JE, Bishop AJ, Farooqi AS, Wargo J, Guadagnolo BAAnnals of surgical oncologyNodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era. Ann Surg Oncol. 2021 Jul; 28(7):3480-3489.Ann Surg Oncol2021-04-15T00:00:002021Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era.33861486Nebhan CA, Johnson DB, Sullivan RJ, Amaria RN, Flaherty KT, Sosman JA, Davies MAThe oncologistEfficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study. Oncologist. 2021 09; 26(9):731-e1498.Oncologist2021-05-04T00:00:002021Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study.Authorship 1019097234021033Saberian C, Amaria RN, Najjar AM, Radvanyi LG, Haymaker CL, Forget MA, Bassett RL, Faria SC, Glitza IC, Alvarez E, Parshottam S, Prieto V, Liz?e G, Wong MK, McQuade JL, Diab A, Yee C, Tawbi HA, Patel S, Shpall EJ, Davies MA, Hwu P, Bernatchez CJournal for immunotherapy of cancerRandomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. J Immunother Cancer. 2021 05; 9(5).J Immunother Cancer2021-05-01T00:00:002021Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma.Authorship 10200091534057733Corsini EM, Mitchell KG, Zhou N, Bernatchez C, Forget MA, Haymaker CL, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Amaria RN, Jazaeri AA, Antonoff MBJournal of surgical oncologyPulmonary resection for tissue harvest in adoptive tumor-infiltrating lymphocyte therapy: Safety and feasibility. J Surg Oncol. 2021 Sep; 124(4):699-703.J Surg Oncol2021-05-31T00:00:002021Pulmonary resection for tissue harvest in adoptive tumor-infiltrating lymphocyte therapy: Safety and feasibility.Authorship 10235324934239137Andrews MC, Duong CPM, Gopalakrishnan V, Iebba V, Chen WS, Derosa L, Khan MAW, Cogdill AP, White MG, Wong MC, Ferrere G, Fluckiger A, Roberti MP, Opolon P, Alou MT, Yonekura S, Roh W, Spencer CN, Curbelo IF, Vence L, Reuben A, Johnson S, Arora R, Morad G, Lastrapes M, Baruch EN, Little L, Gumbs C, Cooper ZA, Prieto PA, Wani K, Lazar AJ, Tetzlaff MT, Hudgens CW, Callahan MK, Adamow M, Postow MA, Ariyan CE, Gaudreau PO, Nezi L, Raoult D, Mihalcioiu C, Elkrief A, Pezo RC, Haydu LE, Simon JM, Tawbi HA, McQuade J, Hwu P, Hwu WJ, Amaria RN, Burton EM, Woodman SE, Watowich S, Diab A, Patel SP, Glitza IC, Wong MK, Zhao L, Zhang J, Ajami NJ, Petrosino J, Jenq RR, Davies MA, Gershenwald JE, Futreal PA, Sharma P, Allison JP, Routy B, Zitvogel L, Wargo JANature medicineGut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. 2021 08; 27(8):1432-1441.Nat Med2021-07-08T00:00:002021Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade.Authorship 10335034Authorship 10340401734771465Sloane RAS, White MG, Witt RG, Banerjee A, Davies MA, Han G, Burton E, Ajami N, Simon JM, Bernatchez C, Haydu LE, Tawbi HA, Gershenwald JE, Keung E, Ross M, McQuade J, Amaria RN, Wani K, Lazar AJ, Woodman SE, Wang L, Andrews MC, Wargo JACancersIdentification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes. Cancers (Basel). 2021 Oct 22; 13(21).Cancers (Basel)2021-10-22T00:00:002021Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes.34724197Patel AB, Farooq S, Welborn M, Amaria RN, Chon SY, Diab A, Glitza Oliva IC, Huen AO, Li SQ, Nelson KC, Pacha O, Patel SP, Rapini RP, Tawbi HA, Wong MK, McQuade J, Davies MA, Haydu LECancerCutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit. Cancer. 2022 03 01; 128(5):975-983.Cancer2021-11-01T00:00:002021Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit.Authorship 1035101934879240St Paul M, Saibil SD, Han S, Israni-Winger K, Lien SC, Laister RC, Sayad A, Penny S, Amaria RN, Haydu LE, Garcia-Batres CR, Kates M, Mulder DT, Robert-Tissot C, Gold MJ, Tran CW, Elford AR, Nguyen LT, Pugh TJ, Pinto DM, Wargo JA, Ohashi PSCell metabolismCoenzyme A fuels T?cell anti-tumor immunity. Cell Metab. 2021 12 07; 33(12):2415-2427.e6.Cell Metab2021-12-07T00:00:002021Coenzyme A fuels T?cell anti-tumor immunity.Authorship 10359135734941392Spencer CN, McQuade JL, Gopalakrishnan V, McCulloch JA, Vetizou M, Cogdill AP, Khan MAW, Zhang X, White MG, Peterson CB, Wong MC, Morad G, Rodgers T, Badger JH, Helmink BA, Andrews MC, Rodrigues RR, Morgun A, Kim YS, Roszik J, Hoffman KL, Zheng J, Zhou Y, Medik YB, Kahn LM, Johnson S, Hudgens CW, Wani K, Gaudreau PO, Harris AL, Jamal MA, Baruch EN, Perez-Guijarro E, Day CP, Merlino G, Pazdrak B, Lochmann BS, Szczepaniak-Sloane RA, Arora R, Anderson J, Zobniw CM, Posada E, Sirmans E, Simon J, Haydu LE, Burton EM, Wang L, Dang M, Clise-Dwyer K, Schneider S, Chapman T, Anang NAS, Duncan S, Toker J, Malke JC, Glitza IC, Amaria RN, Tawbi HA, Diab A, Wong MK, Patel SP, Woodman SE, Davies MA, Ross MI, Gershenwald JE, Lee JE, Hwu P, Jensen V, Samuels Y, Straussman R, Ajami NJ, Nelson KC, Nezi L, Petrosino JF, Futreal PA, Lazar AJ, Hu J, Jenq RR, Tetzlaff MT, Yan Y, Garrett WS, Huttenhower C, Sharma P, Watowich SS, Allison JP, Cohen L, Trinchieri G, Daniel CR, Wargo JAScience (New York, N.Y.)Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021 Dec 24; 374(6575):1632-1640.Science2021-12-23T00:00:002021Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.Authorship 103822510Authorship 103840914Authorship 10408842235190823Creasy CA, Meng YJ, Forget MA, Karpinets T, Tomczak K, Stewart C, Torres-Cabala CA, Pilon-Thomas S, Sarnaik AA, Mul? JJ, Garraway L, Bustos M, Zhang J, Patel SP, Diab A, Glitza IC, Yee C, Tawbi H, Wong MK, McQuade J, Hoon DSB, Davies MA, Hwu P, Amaria RN, Haymaker C, Beroukhim R, Bernatchez CClinical cancer research : an official journal of the American Association for Cancer ResearchGenomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. Clin Cancer Res. 2022 05 02; 28(9):1911-1924.Clin Cancer Res2022-05-02T00:00:002022Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma.35278716Mitra D, Rao PK, Nagarajan P, Bishop AJ, Farooqi AS, Gershenwald JE, Wargo J, Keung EZ, Fisher SB, Amaria RN, Davies MA, Ross MI, Guadagnolo BAPractical radiation oncologyOutcomes After Sphincter-Sparing Local Therapy for Anorectal Melanoma: 1989 to 2020. Pract Radiat Oncol. 2022 Sep-Oct; 12(5):437-445.Pract Radiat Oncol2022-03-09T00:00:002022Outcomes After Sphincter-Sparing Local Therapy for Anorectal Melanoma: 1989 to 2020.35294522Schuler M, Zimmer L, Kim KB, Sosman JA, Ascierto PA, Postow MA, De Vos FYFL, van Herpen CML, Carlino MS, Johnson DB, Berking C, Reddy MB, Harney AS, Berlin JD, Amaria RNClinical cancer research : an official journal of the American Association for Cancer ResearchPhase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma. Clin Cancer Res. 2022 07 15; 28(14):3002-3010.Clin Cancer Res2022-07-15T00:00:002022Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma.Authorship 1044600435476655Menzies AM, Pires da Silva I, Trojaniello C, Vieu E, Amaria RN, Zimmer L, Lo SN, Burton EM, Tawbi HA, Schadendorf D, Grob JJ, Ascierto PA, Long GVThe New England journal of medicineCTLA-4 Blockade Resistance after Relatlimab and Nivolumab. N Engl J Med. 2022 04 28; 386(17):1668-1669.N Engl J Med2022-04-28T00:00:002022CTLA-4 Blockade Resistance after Relatlimab and Nivolumab.Authorship 104805121Authorship 1048065235705814Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JANatureAndrogen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2022 06; 606(7915):797-803.Nature2022-06-15T00:00:002022Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.35706041Burton EM, Amaria RN, Cascone T, Chalabi M, Gross ND, Mittendorf EA, Scolyer RA, Sharma P, Ascierto PAJournal of translational medicineNeoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge-December 1st-2nd, 2021. J Transl Med. 2022 06 15; 20(1):271.J Transl Med2022-06-15T00:00:002022Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge-December 1st-2nd, 2021.Authorship 105788422Authorship 10568229Authorship 10549321Authorship 10566612936289334Amaria RN, Postow M, Burton EM, Tetzlaff MT, Ross MI, Torres-Cabala C, Glitza IC, Duan F, Milton DR, Busam K, Simpson L, McQuade JL, Wong MK, Gershenwald JE, Lee JE, Goepfert RP, Keung EZ, Fisher SB, Betof-Warner A, Shoushtari AN, Callahan M, Coit D, Bartlett EK, Bello D, Momtaz P, Nicholas C, Gu A, Zhang X, Korivi BR, Patnana M, Patel SP, Diab A, Lucci A, Prieto VG, Davies MA, Allison JP, Sharma P, Wargo JA, Ariyan C, Tawbi HANatureNeoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2022 11; 611(7934):155-160.Nature2022-10-26T00:00:002022Neoadjuvant relatlimab and nivolumab in resectable melanoma.36324592Ho J, Mattei J, Tetzlaff M, Williams MD, Davies MA, Diab A, Oliva ICG, McQuade J, Patel SP, Tawbi H, Wong MK, Fisher SB, Hanna E, Keung EZ, Ross M, Weiser R, Su SY, Frumovitz M, Meyer LA, Jazaeri A, Pettaway CA, Guadagnolo BA, Bishop AJ, Mitra D, Farooqi A, Bassett R, Faria S, Nagarajan P, Amaria RNFrontiers in oncologyNeoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma. Front Oncol. 2022; 12:1001150.Front Oncol2022-10-17T00:00:002022Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma.36229264Mitra D, Farr M, Nagarajan P, Ho J, Bishop AJ, Jhingran A, Farooqi AS, Frumovitz M, Amaria RN, McQuade JL, Jazaeri AA, Guadagnolo BAGynecologic oncologyGynecologic tract melanoma in the contemporary therapeutic era: High rates of local and distant disease progression. Gynecol Oncol. 2022 Dec; 167(3):483-489.Gynecol Oncol2022-10-11T00:00:002022Gynecologic tract melanoma in the contemporary therapeutic era: High rates of local and distant disease progression.36627494Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JANatureAuthor Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2023 Jan; 613(7945):E3.Nature2023-01-01T00:00:002023Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.Authorship 1065298136894629Amaria RN, Postow M, Burton EM, Tetzlaff MT, Ross MI, Torres-Cabala C, Glitza IC, Duan F, Milton DR, Busam K, Simpson L, McQuade JL, Wong MK, Gershenwald JE, Lee JE, Goepfert RP, Keung EZ, Fisher SB, Betof-Warner A, Shoushtari AN, Callahan M, Coit D, Bartlett EK, Bello D, Momtaz P, Nicholas C, Gu A, Zhang X, Korivi BR, Patnana M, Patel SP, Diab A, Lucci A, Prieto VG, Davies MA, Allison JP, Sharma P, Wargo JA, Ariyan C, Tawbi HANatureAuthor Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2023 Mar; 615(7953):E23.Nature2023-03-01T00:00:002023Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma.Authorship 10674401836997799Glitza Oliva IC, Ferguson SD, Bassett R, Foster AP, John I, Hennegan TD, Rohlfs M, Richard J, Iqbal M, Dett T, Lacey C, Jackson N, Rodgers T, Phillips S, Duncan S, Haydu L, Lin R, Amaria RN, Wong MK, Diab A, Yee C, Patel SP, McQuade JL, Fischer GM, McCutcheon IE, O'Brien BJ, Tummala S, Debnam M, Guha-Thakurta N, Wargo JA, Burton EM, Tawbi HA, Davies MANature medicineConcurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med. 2023 04; 29(4):898-905.Nat Med2023-03-30T00:00:002023Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.Authorship 1068552637116111Hieken TJ, Kreidieh F, Aedo-Lopez V, Block MS, McArthur GA, Amaria RNAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual MeetingNeoadjuvant Immunotherapy in Melanoma: The Paradigm Shift. Am Soc Clin Oncol Educ Book. 2023 Jan; 43:e390614.Am Soc Clin Oncol Educ Book2023-01-01T00:00:002023Neoadjuvant Immunotherapy in Melanoma: The Paradigm Shift.Authorship 107083219Authorship 1070345437193799Garbe C, Dummer R, Amaral T, Amaria RN, Ascierto PA, Burton EM, Dreno B, Eggermont AMM, Hauschild A, Hoeller C, Kaufmann R, Lebbe C, Mandala M, Menzies AM, Moreno D, Michielin O, Nathan P, Patel SP, Robert C, Schadendorf D, Lorigan PC, Scolyer RA, Tawbi HA, van de Wiel BA, Blank C, Long GVNature medicineNeoadjuvant immunotherapy for melanoma is now ready for clinical practice. Nat Med. 2023 Jun; 29(6):1310-1312.Nat Med2023-06-01T00:00:002023Neoadjuvant immunotherapy for melanoma is now ready for clinical practice.37150813Marques-Piubelli ML, Seervai RNH, Mudaliar KM, Ma W, Milton DR, Wang J, Muhlbauer A, Parra ER, Solis LM, Nagarajan P, Speiser J, Hudgens C, Cho WC, Aung PP, Patel A, Pacha O, Nelson KC, Tetzlaff MT, Amaria RN, Torres-Cabala CA, Prieto VG, Wistuba II, Curry JLJournal of cutaneous pathologyGene expression profiling and multiplex immunofluorescence analysis of bullous pemphigoid immune-related adverse event reveal upregulation of toll-like receptor 4/complement-induced innate immune response and increased density of TH 1 T-cells. J Cutan Pathol. 2023 Jul; 50(7):661-673.J Cutan Pathol2023-05-07T00:00:002023Gene expression profiling and multiplex immunofluorescence analysis of bullous pemphigoid immune-related adverse event reveal upregulation of toll-like receptor 4/complement-induced innate immune response and increased density of TH 1 T-cells.Authorship 1088417138309721Amaria R, Knisely A, Vining D, Kopetz S, Overman MJ, Javle M, Antonoff MB, Tzeng CD, Wolff RA, Pant S, Lito K, Rangel K, Fellman B, Yuan Y, Lu KH, Sakellariou-Thompson D, Haymaker CL, Forget MA, Hwu P, Bernatchez C, Jazaeri AAJournal for immunotherapy of cancerEfficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. J Immunother Cancer. 2024 Feb 02; 12(2).J Immunother Cancer2024-02-02T00:00:002024Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.Authorship 1089690438423748Betof Warner A, Hamid O, Komanduri K, Amaria R, Butler MO, Haanen J, Nikiforow S, Puzanov I, Sarnaik A, Bishop MR, Schoenfeld AJJournal for immunotherapy of cancerExpert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy. J Immunother Cancer. 2024 Feb 29; 12(2).J Immunother Cancer2024-02-29T00:00:002024Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy.true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1Associate ProfessorAssociate Professortrue1Associate ProfessorAssociate Professortrue1Assistant ProfessorAssistant Professortrue1Assistant ProfessorAssistant Professortrue1Associate ProfessorAssociate Professor